Ranjit  Bindra , MD, PhD

Ranjit Bindra , MD, PhD

Yale Cancer Center/Smilow Cancer Hospital

Harvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology; Vice Chair for Translational Research, Therapeutic Radiology; Scientific Director, Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center

Expertise: Brain CancerTherapeutic RadiologyPathology

Dr. Ranjit Bindra is a physician-scientist at Yale School of Medicine and Co-Director of the Yale Brain Tumor Center at Smilow Cancer Hospital. In the laboratory, his group recently led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and Nature, and it has received international attention with major clinical implications Dr. Bindra is now translating this work directly into patients, in four phase I/II clinical trials, including an innovative, biomarker-driven trial specifically targeting the Adolescent/Young Adult (AYA) cancer patient population. In addition, he is lead co-PI of a 35-site, NCI-sponsored Phase II trial testing the PARP inhibitor, olaparib, in adult IDH1/2-mutant solid tumors (NCT03212274). As a biotech entrepreneur he recently co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment. Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center (MSKCC) in 2012.

Education & Training
Memorial Sloan-Kettering Cancer Center (2012)
Memorial Sloan-Kettering Cancer Center (2008)
Yale University School of Medicine (2007)
Yale University Graduate School (2005)
Yale University (1998)

No Clipping

No Research/Citations

Nanoparticles Deliver Treatment Directly to Tumors of Deadly Brain Cancer

Using nanoparticles administered directly into the cerebrospinal fluid (CSF), a research team has developed a treatment that may overcome significant challenges in treating a particularly deadly brain cancer.
01-Nov-2023 04:05:58 PM EDT

No Quotes

Available for logged-in users onlyLogin HereorRegister

No Video